222 findings · Cellular · published 2025+
- CellularStrong
MitoQ supplementation did not alter acute exercise-induced redox responses in skeletal muscle.
MitoQ does not affect redox signaling during acute exercise in older adults.
Refutes 2025New - CellularStrong
HbA1C levels increase alongside the duration of illness in individuals with type 2 diabetes.
Practitioners should monitor HbA1C levels to assess disease progression in diabetic patients.
Supports 2025New - CellularGood
Observational data suggest GLP-1 RAs improve walking distance in peripheral artery disease.
GLP-1 RAs may enhance mobility in patients with peripheral artery disease.
Supports 2025New - CellularGood
Tirzepatide may result in an increase in non-serious adverse events (risk ratio 1.33, 95% CI 1.03 to 1.71) compared to placebo.
Clinicians should monitor for non-serious adverse events when prescribing tirzepatide.
Qualifies 2025New - CellularGood
Incretin therapies could ameliorate fatty liver disease, chronic inflammation, sleep apnea, and possibly degenerative bone disorders and cognitive decline.
Incretin therapies may be considered for patients with these co-morbidities, pending further research.
Qualifies 2025New - CellularGood
Baseline disease severity, depressive symptoms, insulin resistance, and preperitoneal fat were negatively associated with PASI improvement.
Understanding these associations can help tailor treatment strategies for better outcomes.
Supports 2025New